These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 30458931)

  • 21. Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5).
    Verheugt FWA; Ten Berg JM; Storey RF; Cuisset T; Granger CB
    J Am Coll Cardiol; 2019 Aug; 74(5):699-711. PubMed ID: 31277840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation.
    Douros A; Renoux C; Yin H; Filion KB; Suissa S; Azoulay L
    Am J Med; 2019 Feb; 132(2):191-199.e12. PubMed ID: 30691551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?
    Peterson BE; Bhatt DL
    Curr Cardiol Rep; 2018 Sep; 20(11):110. PubMed ID: 30259187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.
    Oldgren J; Wallentin L; Alexander JH; James S; Jönelid B; Steg G; Sundström J
    Eur Heart J; 2013 Jun; 34(22):1670-80. PubMed ID: 23470494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
    Lam DH; Bell SM; Hira RS
    Curr Atheroscler Rep; 2018 Jan; 20(1):4. PubMed ID: 29349596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic regimens in patients with indication for long-term anticoagulation undergoing coronary interventions-systematic analysis, review of literature, and implications on management.
    Deshmukh A; Hilleman DE; Del Core M; Nair CK
    Am J Ther; 2013; 20(6):654-63. PubMed ID: 21519218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
    Barbieri L; Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):611-622. PubMed ID: 27757726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis.
    Dawwas GK; Barnes GD; Dietrich E; Cuker A; Leonard CE; Genuardi MV; Lewis JD
    Am Heart J; 2021 Dec; 242():71-81. PubMed ID: 34450051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
    Kang DO; Yu CW; Kim HD; Cho JY; Joo HJ; Choi RK; Park JS; Lee HJ; Kim JS; Park JH; Hong SJ; Lim DS
    Coron Artery Dis; 2015 Aug; 26(5):372-80. PubMed ID: 25768244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Koskinas KC; Räber L; Zanchin T; Pilgrim T; Stortecky S; Hunziker L; Blöchlinger S; Billinger M; Gartwyl F; Moro C; Moschovitis A; Jüni P; Heg D; Windecker S
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1473-83. PubMed ID: 27478115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
    Enomoto Y; Iijima R; Tokue M; Ito N; Nagashima Y; Araki T; Yamazaki K; Utsunomiya M; Hori M; Itaya H; Shiba M; Hara H; Nakamura M; Sugi K
    Cardiovasc Interv Ther; 2014 Jul; 29(3):193-9. PubMed ID: 24366503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease.
    Gurbel PA; Fox KAA; Tantry US; Ten Cate H; Weitz JI
    Circulation; 2019 Apr; 139(18):2170-2185. PubMed ID: 31034291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.
    Fortuni F; Ferlini M; Leonardi S; Angelini F; Crimi G; Somaschini A; Cornara S; Potenza A; De Servi S; Oltrona Visconti L; De Ferrari GM
    Int J Cardiol; 2018 Dec; 273():80-87. PubMed ID: 30115419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
    Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
    Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.